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ABSTRACT
Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median
15.7 months, 13.1–17.8), with only a 23% response rate to monotherapy treatment with anti-PDL1
checkpoint immunotherapy. To identify new therapeutic targets, we profiled the immune regulatory
signatures during murine cancer development using the BBN carcinogen and identified an increase in
the expression of the T cell inhibitory protein B7-H4 (VTCN1, B7S1, B7X). B7-H4 expression temporally
correlated with decreased lymphocyte infiltration. While the increase in B7-H4 expression within the
bladder by CD11b+ monocytes is shared with human cancers, B7-H4 expression has not been previously
identified in other murine cancer models. Higher expression of B7-H4 was associated with worse survival
in muscle-invasive bladder cancer in humans, and increased B7-H4 expression was identified in luminal
and luminal-papillary subtypes of bladder cancer. Evaluation of B7-H4 by single-cell RNA-Seq and
immune mass cytometry of human bladder tumors found that B7-H4 is expressed in both the epithelium
of urothelial carcinoma and CD68+ macrophages within the tumor. To investigate the function of B7-H4,
treatment of human monocyte and T cell co-cultures with a B7-H4 blocking antibody resulted in
enhanced IFN-γ secretion by CD4+ and CD8+ T cells. Additionally, anti-B7-H4 antibody treatment of BBN-
carcinogen bladder cancers resulted in decreased tumor size, increased CD8+ T cell infiltration within the
bladder, and a complimentary decrease in tumor-infiltrating T regulatory cells (Tregs). Furthermore,
treatment with a combination of anti-PD-1 and anti-B7-H4 antibodies resulted in a significant reduction
in tumor stage, a reduction in tumor size, and an increased level of tumor necrosis. These findings
suggest that antibodies targeting B7-H4 may be a viable strategy for bladder cancers unresponsive to
PD-1 checkpoint inhibitors.
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Introduction
Genetic alterations result in the expression of neoantigens that
may be recognized by cells of the innate and adaptive immune
system, which in turn generate the anti-tumor immune
response.1 However, many tumors are able to evade this
response by upregulating checkpoint inhibitors that suppress
immune activation, as well as tumor-infiltrating immune cells
that increase the expression of regulatory proteins. Therefore,
the anti-tumor immune response is dynamic and evasion of the
immune system by the tumor is a hallmark of cancer. While
CTLA-4 and PD-L1 are the most well-described checkpoint
proteins, B7-H4 (B7S1, B7x, VTCN1), a B7-family member
expressed on antigen-presenting cells and/or tumors, can inhibit
T cell-mediated inflammatory responses.2 B7-H4 has been pri-
marily investigated as an inhibitor of autoimmune disease with
agonistic application of the B7-H4-immunoglobulin fusion pro-
tein (B7-H4Ig) [as reviewed in2]. Data show that B7-H4
functionally decreases inflammatory CD4+ T cells directly and
indirectly via B7-H4-induced increases in both the number and
function of regulatory CD4+ T cells (Tregs).3-5
B7-H4 expression in renal cell carcinoma,6-8 melanoma,9
breast,10 lung,11,12 gastric,13 colorectal,14 pancreatic,15
prostate,16 endometrial,17 and ovarian18-20 cancer is associated
with increased tumor size, cancer stage, metastasis, progres-
sion, poor disease prognosis, decreased survival, and/or
decreased infiltration of T cells. Targeted genetic deletion of
B7-H4 (Vtcn1) in an orthotopic model of liver cancer is
associated with increased CD8+ T cell tumor infiltration
with decreased markers of exhaustion.21 Therefore, inhibition
of B7-H4 may be an alternative strategy to reinvigorate
tumor-specific T cell responses. Yet, the therapeutic applica-
tion of B7-H4 blocking antibodies has not been demonstrated
in murine models due to a lack of B7-H4 expression within
tumor cell line mouse models.
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Urothelial carcinoma is the fifth most common cancer in
the US, and has the second-worst survival for patients with
metastasis at only 5% within 5 years.22 While systemic che-
motherapy was the standard of care for treatment of patients
with metastatic urothelial carcinoma with a median survival
of 13.1 months (range 11.7 to 15.1), in 2016 antibodies target-
ing immune checkpoint blockade (ICB), specifically PD-1 and
PD-L1 were approved by the FDA.23 However, only 3-21% of
patients with metastatic urothelial carcinoma that is refractory
to chemotherapy will respond to ICB.24 While the factors that
determine clinical response are not completely known, fea-
tures such as immune cell infiltration and high total mutation
burden have been associated with an increased response.25
Not all studies have demonstrated that PD-L1 expression is
associated with improved survival following anti-PD-1 ther-
apy, suggesting that multiple aspects of the regulation of
immune responses remain unclear.26 Thus, most patients
with metastatic urothelial cancer are unresponsive to ICB,
and these patients may benefit from additional therapies
that target distinct and non-overlapping immune regulatory
pathways.
Materials and methods
Tumor preparation for single-cell RNA-seq
Tumor samples were obtained prospectively after IRB
approval at Northwestern (STU00088853). Tumor specimen
was minced and enzymatically dissociated DMEM supple-
mented with Liberase TM (0.0625 mg/ml) and DNase
I (Sigma, D5025, 0.2 mg/mL) for 30 min. Every 10-min speci-
men was gently pipetted and enzyme mix was exchanged for
freshly made enzyme mix. After dissociation tissue was spun
down at 1300 RPM for 7 min and filtered to through a 100
um filter to yield a single-cell suspension. Cells were spun
down, resuspended in PBS supplemented with 0.5% BSA and
2 mmol/L EDTA and stained with PI (BD) and Calcein Violet
(Invitrogen). Viable cells were sorted using BD FACS Aria
Fusion instrument. Sorted cells were washed and resuspended
in PBS containing 0.04% BSA. Cells were counted on
Countess II automated cell counter (Thermo Fisher) 12,000
cells were loaded per lane onto a 10X Chromium microfluidic
chip. Single-cell capture, barcoding, and library preparation
were performed using the 10X Chromium version 2 chemistry
according to the manufacturer’s protocol (#CG00052). cDNA
and libraries were checked for quality on Agilent 4200
Tapestation and quantified by KAPA qPCR before sequencing
on a single lane of a HiSeq4000 (Illumina) to an average depth
of 50,000 reads per cell.
Single-cell data processing
The Cell Ranger pipeline (v1.2, 10X Genomics) was used to
convert Illumina base call files to FASTQ files, align FASTQs
to the GRCH38 reference (v3.0.0, 10X Genomics) for human
samples to produce a digital gene-cell counts matrix. The
resultant gene-cell matrix was filtered to remove cells with
fewer than 500 transcripts and genes with fewer than two
counts in two cells. The gene-cell matrices were then
normalized such that the number of unique molecular identi-
fiers (UMI) in each cell is equal to the median UMI count
across the data set and log transformed. Expression at 1,000
highly variable genes in each data set, selected as the genes
with the highest dispersion, was used to reduce the dimen-
sionality of the data sets to three dimensions using Uniform
Manifold Approximation and Projection (UMAP) and cells
were clustered using Leiden-based clustering in the UMAP
space. Genes of interest were plotted in UMAP space using
adjusted values based on Markov Affinity-based Graph
Imputation (MAGIC) of the raw gene-cell counts matrix.
Multiplexed imaging by IMC
Formalin-fixed paraffin-embedded human Ta NMIBC tissues
were cut into 5-μm sections and mounted on slides. Slides
were incubated for 15 min at 55°C in a dry oven, deparaffi-
nized in fresh histoclear, and rehydrated through a series of
graded alcohols. Antigen retrieval was performed in
a decloaking chamber (BioSB TintoRetriever) for 15 min at
95°C in Citrate Buffer. After blocking in buffer containing 3%
BSA, slides were incubated overnight at 4°C with a cocktail of
metal-conjugated IMC-validated primary antibodies. The
following day, slides were washed twice in Dulbecco’s
Phosphate-Buffered Saline and counterstained with iridium
intercalator (0.25 μmol/L) for 5 min at room temperature, to
visualize the DNA. After a final wash in ddH20, the slides
were air-dried for 20 min. The slides were then loaded on the
Fluidigm Hyperion imaging mass cytometer. Regions of inter-
est were selected using the acquisition software and ablated by
the Hyperion. The resulting images were exported as 16-bit .
tiff files using the Fluidigm MCDViewer software and ana-
lyzed using the open-source Histocat++ toolbox.
Mice and tumor staging
Mice were cared for in a fashion supervised by the ACUC at
Northwestern University and all research was approved in an
animal research protocol. Male C57BL/6 mice at least 6 weeks
old received N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)
at a dose of 0.05% in drinking water ad libitum. After
20 weeks of exposure, mice were randomized to therapy
which included treatment with IgG (200 μg/kg, BioXcell),
anti-PD1 (200 μg/kg, BioXcell), and/or anti-B7-H4 (200 μg/
mouse, from Amplimmune). Mice were injected with four
weekly doses. At the end of treatment, animals were eutha-
nized by CO2 with secondary cervical dislocation. Bladders
were removed and divided in the sagittal plane, and either
fixed in 10% formalin or snap-frozen in liquid nitrogen.
Pathology was staged using human AJCC staging of the
degree of bladder wall invasion.
Tumor morphometry
All paraffin-embedded surgical specimens were sent to the
pathology core for hematoxylin and eosin (HE) staining. To
quantify the amount of tumor in each bladder specimen, the
HE stained slides were scanned at low magnification and
digitized using the TissueFAXS system (TissueGnostics, Los
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Angeles, CA, USA). The acquired images were analyzed using
HistoQuest cell analysis software (TissueGnostics).
First, the borders of the specimen were identified. This was
done by using the automated region of interest (ROI) function
on HistoQuest. Next, the lumen (if visible) and any non-
urinary bladder components (i.e. prostate, uterus, ureter)
that were included on the auto-ROI function were manually
excluded. The total area of the specimen was calculated by
taking the area identified by the auto-ROI function and sub-
tracting the area of the lumen and any non-bladder compo-
nent. Once the total specimen area was quantified, the tumor
burden was manually quantified using the HistoQuest soft-
ware. In each slide, the individual areas of the tumor were
encircled (representative example shown in Supplemental
Figure 4). Each area of tumor was then denoted to be either
necrotic or non-necrotic tumor. Total tumor burden (includ-
ing necrotic tumor) and total necrotic tumor burden were
recorded for each slide. Percentage tumor burden was calcu-
lated by dividing the total tumor burden of a specimen by the
total area of the specimen.
RNA extraction, library creation, and RNA-seq
Mouse tumors were ground using liquid nitrogen and
a mortar and pestle, and then RNA was extracted using
Trizol Reagent (Thermo Fisher Scientific) following manufac-
turer’s instructions. RNA quality and concentration were
assessed by NanoDrop and then Qubit Fluorometric
Quantitation (Thermo Fisher Scientific). Library preparation
and RNAseq were performed at the NuSeq core facility
(Northwestern University) using an Illumina HiSeq 2000.
Immunohistochemistry
Bladders were fixed in 10% formalin and embedded in paraf-
fin. Four micron thick sections were used for IHC staining for
CD8 (1:1000, #MA5-13263, Invitrogen) and Foxp3 (1:400,
#12653, Cell Signaling). IHC was performed using a Dako
Autostainer Plus instrument (Dako, CO, USA), and anti-
rabbit Dako EnVision+System-HRP (Dako). For each tumor,
the HRP positive cells were counted per low-power (10X
objective) field. Each tumor was evaluated with at least six
fields in two separate sections.
Human CD14+ monocyte plus T cell co-cultures
PMBCs from healthy donors (n = 5) (LifeSource; Evanston, IL)
were collected and CD14+monocytes were purified via AutoMacs
Magnetic Bead cell separation technology. The CD14-fractions
were collected, and CD4+ and CD8+ T cells purified via
AutoMacs Magnetic Bead cell separation technology. The auto-
logous CD4+ and CD8 + T cells were cryopreserved for use in the
monocyte/T cell co-cultures. The CD14+ monocytes were cul-
tured in the presence of medium alone, recombinant human IL-
6, recombinant human IL-10, or recombinant human IL-6 plus
recombinant human IL-10 (20 ng/ml) at 5 × 106 cells/well in
6-well plates at a final volume of 2 ml in cRPMI w/10% FCS for
3 days. On day 3 of culture, the non-adherent cells were removed,
and the adherent monocytes collected following incubation in
presence of 1 ml of 1xDPBS containing 2 mM EDTA, and
incubate the plates at 37°C for 15 min. The cryopreserved CD4+
and CD8+ T cells were thawed, washed, and stained with CFSE.
For the macrophage/T cell co-cultures, the cells were cultured in
flat-bottomed 96-well plates. The wells were coated with anti-CD3
(0.5 µg/ml; 100 µl/well; coating wells for 2 h at 37°C; wells washed
3x with 1x DPBS), and the appropriate amount of Control Ab or
anti-B7-H4 was added. For the assessment of T cells proliferation,
the T cells were collected, washed in PBS, stained with LIVE/
DEAD® Fixable Aqua Dead Cell Stain (Life Technologies; Grand
Island, NY), blockedwith anti-CD16/32 (ThermoFisher Scientific;
San Jose, CA), and then stained with the indicated antibodies –
anti-CD4 (clone OKT4) or anti-CD8 (clone 3B5). Results are
expressed as the mean percentage of proliferated CD4+ and
CD8+ T cells. For cytokine analysis replicate wells were harvested
on day +3 of co-culture and cytokine secretion determined via
multiplex Luminex LiquiChip (Millipore).
Mouse lymph node cultures
Lymph nodes were collected from naïve SJL/J mice, and cells
made into a single-cell suspensions. CFSE-labeled total lymph
node cells (5x105 cells/well) were cultured in the presence of
anti-CD3 (1 µg/ml), plus Control Ig, hB7-H4Ig, anti-B7-H4, or
hB7-H4Ig plus anti-B7-H4 (5 µg/ml). The cells were cultured
for 5 days. For the assessment of T cells proliferation, the T cells
were collected, washed in PBS, stained with LIVE/DEAD®
Fixable Aqua Dead Cell Stain (Life Technologies; Grand
Island, NY), blocked with anti-CD16/32 (ThermoFisher
Scientific; San Jose, CA), and then stained with the indicated
antibodies – anti-CD4 (clone RM4-5). Replicate wells were
pulsed with 1µCi of tritiated thymidine at 24 h, and the cultures
were harvested on day +5.
PLP139-151/CFA Induced EAE and DTH. 6–7 week-old
female SJL/J mice were immunized s.c. with 100 μl of an
emulsion containing 200 μg of M. tuberculosis H37Ra (BD
Biosciences; San Jose, CA) and 50 µg of PLP139–151 distributed
over three sites on the flank. Mice were treated with Control
Ig, hB7-H4Ig, and anti-B7-H4 beginning at the time of prim-
ing. Mice were treated with 100 µg per dose of injections 3x
per week for 2 weeks via i.p. injection. Individual animals
were observed at the indicated time points and clinical scores
assessed in a blinded fashion on a 0–5 scale: 0, no abnorm-
ality; 1, limp tail; 2, limp tail and hind limb weakness; 3, hind
limb paralysis; 4, hind limb paralysis and forelimb weakness;
and 5, moribund. The data are reported as the mean daily
clinical score. On day +9 post priming, mice were assayed for
delayed-type hypersensitivity (DTH). Mice were anaesthetized
by inhalation of isoflurane and the thickness of both ears was
measured using a dial thickness gauge. 10 µg of PLP139-151
(negative control) and OVA protein in 10 µl of PBS was
injected into the left and right ear, respectively. The increase
in ear thickness was determined after 24 h.
Flow cytometry
For cell, analysis spleens were dissociated into a single-cell
suspensions and RBCs lysed. For the bladder leukocytes,
Single-cell suspensions were prepared by mincing the bladder
tissue in 2 ml of Accutase (MilliPore) plus 1 mg/ml collage-
nase, and the samples were incubated at 37°C for 30 min.
Following the enzyme digestion, the bladder samples were
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disrupted with a 100 µm cell strainer, the cell strainer washed
2x with 10 ml of HBSS+ 5% FCS, and the cells pelleted. The
cells were washed in PBS, stained with LIVE/DEAD® Fixable
Aqua Dead Cell Stain (Life Technologies; Grand Island, NY),
blocked with anti-CD16/32 (ThermoFisher Scientific), and
then stained with the indicated antibodies. 106 viable cells
were analyzed per individual sample using a BD LSRFortessa
(BD Bioscience), and the data analyzed using FloJo Version
9.5.2 software (Tree Star, Inc.; Ashland, OR).
Bioinformatics
To compare expression across early time points of BBN expo-
sure, the CPM values for the replicates were calculated with
EdgeR and then averaged together at each time point. They
were then log2 transformed and mean centered. A heatmap
was produced with the R package Pheatmap.
Clinical, mRNA seq, and mutation data from The Cancer
Genome Atlas (TCGA) bladder urothelial carcinoma dataset was
downloaded from the Broad Institute Genome Data Analysis
Center (GDAC) using TCGA data version 2016_01_28 (http://
gdac.broadinstitute.org).27,28 Analysis was performed with
R v3.5.1 utilizing Bioconductor v3.9. RNA-seq mRNA expres-
sion levels are presented as RNA-seq by expectation-
maximization (RSEM) values, and z-score >2 was used to define
overexpression.29 Overall survival outcomes were calculated
using the log-rank test and R packages survival v2.43–3 and
survminer v0.4.3. Pan-cancer expression profile of B7-H4
(VTCN1) was extracted from the Broad GDAC Firehose
v1.1.38 (http://firebrowse.org/). Spearman correlations between
B7-H4, PD-1, PD-L1, and CTLA-4 expression and mutation,
neoantigen, and APOBEC enrichment was performed using
ggplot2 v3.1.0. Molecular subtypes (luminal, luminal-papillary,
luminal-infiltrated, basal-squamous, and neuronal) were
assigned as previously described.30 Comparison of expression
between subtypes was performed using Kruskal–Wallis
ANOVA. Immune signatures were calculated as previously
described.31-33 Hierarchical clustering of immune signatures in
among molecular subtypes was performed with multiClust v1.4.0
and gplots v3.0.1.34 Correlation heatmap of immune signatures
and B7-H4 expression was created using ggplot2 v3.1.0.
For murine tumors, following quality control and adapter
trimming, reads were mapped to mm10 genome using
STAR,35 and then counted using HTSeq.36 Gene counts
were converted to CPM and further analyzed in R using the
Bioconductor packages limma and edgeR. Limma was used to
generate MDS plots and call differentially expressed (DE)
genes. Top DE genes were visualized by Volcano plots, and
used for Pathway Analysis that was conducted using the
Bioconductor packages TopGO and ReactomePA.37 The
most significant pathways (reactomeDB terms) enriched in
DE genes were shown by horizontal barplots, where color
intensity tracked with p-values (computed by Fisher Exact
test).
Statistical Analysis Comparisons of the percentage of ani-
mals showing clinical disease were analyzed by Χ2 using Fisher’s
exact probability, and two-way ANOVA with a Bonferroni
posttest was used to determine statistical differences.
Results
B7-H4 expression increases during bladder cancer
development and is associated with worse survival in
human bladder cancer
To investigate immune regulators of bladder cancer initiation
and progression, we used the carcinogen-induced male C57BL/
6 mouse model of bladder cancer derived from timed exposure
to N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN). Our
laboratory has previously validated the genomic features of
this model in which tumors develop from superficial cancer
and progress to muscle-invasive bladder cancer (MIBC)
between three and 5 months after initial exposure.38
Evaluation of the mutation signature most closely aligns with
those caused by smoking, justifying the clinical relevance of
BBN to human bladder cancer, in which over 60% of cancers
are attributed to smoking-related carcinogens.39 The BBN
model offers a distinct advantage that immune effector and
regulatory processes can be assessed both in the bladder and
peripheral immune organs from the point of tumor initiation
until the development of tumors. Therefore, C57BL/6 (B6)
mice were provided BBN and gene expression profiling was
performed early (1, 2, and 4 weeks) after exposure to the
carcinogen. We identified an early expression profile of
immune response-related genes that increased over time fol-
lowing BBN exposure (Figure 1a). This included transcripts for
CD8, CD4, and pathways associated with the regulation of
inflammation. For example, markers of T cell exhaustion (PD-
1, LAG-3, and Tim-3) and regulation (Foxp3 and Nrp-1)
increased by 2 weeks, and B7-H4, a protein expressed by
APCs that is known to inhibit T cell function via both direct
and indirect mechanisms,5,40 was significantly increased by
4 weeks and corresponded to a decrease in CD8 and CD4
transcripts present within the bladder (Figure 1a). To deter-
mine if B7-H4 may play a role in human bladder cancer, we
evaluated the expression of B7-H4 in the cancer genome atlas
for MIBC. Patients with high expression of B7-H4 had signifi-
cantly worse overall survival compared to those with lower
expression (21.85 vs 34.03 months, p = .03) (Figure 1b).
Unlike other immune checkpoints (such as PD-1, PD-L1, and
CTLA-4), expression of B7-H4 does not appear to correlate
with neoantigens, total mutation burden, APOBEC mutations,
or gene signatures (Supplemental Figure 1). We also found
significant B7-H4 enrichment in the bladder tumor subtypes
that had relatively low expression of PD-1, PD-L1, and CTLA-4
including luminal, luminal papillary and luminal-infiltrated
tumors using the 2017 TCGA molecular subtyping classifica-
tion (Figure 1c). While the response to anti-PD-1 therapy is
correlated with the expression of PD-L1, identification of
a treatment that functions independent of PD-1/PD-L1 could
lead to improved overall outcomes for patients. Thus, we were
interested in the localization of B7-H4 expression in bladder
cancers, including localization in the tumor and tumor micro-
environment. Using immunohistochemistry, we found expres-
sion of B7-H4 localized to immune cells present within healthy
human bladder, with increased expression of B7-H4 in higher
grade urothelial tumors as compared to low-grade urothelial
tumors (Figure 1d, left and middle panels). While most mouse
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tumor in vivo models do not contain B7-H4 expressing cells,
our data show that B7-H4 is expressed in the BBN mouse
model, and B7-H4 expression co-localized with CD11b+ mye-
loid cells (Figure 1d, right; Supplemental Figure 2). This sug-
gests that the expression of B7-H4 was likely localized to the
myeloid lineage cells only, and B7-H4 is not expressed by the
tumor cells in the BBN mouse model. These data are consistent
with human tumors in which B7-H4 was not expressed in basal
tumors. To confirm the localization of B7-H4 in human
tumors, we performed single-cell RNA-Seq of a stage Ta high-
grade bladder tumor (Figure 1e). VTCN1 (B7H4) mRNA was
detected on both urothelial cells (EPCAM+) and myeloid cells
(CD68+) by scRNA sequencing. While VTCN1 was expressed
ubiquitously throughout the urothelial clusters at the mRNA
transcript level, B7-H4 protein was not detected on these cells.
In contrast, analysis of myeloid cells showed scattered VTCN1
Figure 1. B7-H4 is expressed by bladder cancer andmyeloid cells in human andmurine bladder cancer. (a) Heat map ofmRNAs of immune regulatory genes at 1, 2 and 4weeks
of BBN exposure. (b) Overall survival of the muscle invasive bladder cancers (MIBC) from the TCGA identifying worse survival for patients with high levels of VTCN1 (B7-H4). (c)
Muscle invasive bladder cancers (MIBC, Stage II or greater) can be grouped by intrinsic tumor subtype. We performed subtype analysis of MIBCs from the TCGA and grouped
them by subptype. In contrast to tumor subtype (like basal tumors) that express high levels of other immune regulatory proteins, like PD-L1, B7-H4 is more highly expressed in
luminal and luminal-infiltrated tumors, (d) Immunohistochemistry of B7-H4 in normal human bladder, low grade noninvasive (stage TaLG), and invasive (Stage T1HG)
demonstrating expression on tumor and infiltrating leuckocytes and in BBNmouse bladder tumor demonstrating expression only on infiltrating leukocytes (20X magnification).
These localizations in human bladder cancer were confirmedby single-cell RNA-seq of a low-grade Ta tumor (e) showing high expression in luminal cells (EPCAM+) and scattered
expression in myeloid cells (CD68+). Imaging mass cytometry applied to FFPE NMIBC section showing expression of B7H4 (white), smooth muscle actin (green) and pan-keratin
(red). B7H4 was localized to the tumor stromal region (pan-keratin negative) (left). Same image as in (left) with the addition of CD68 (magenta) showing colocalization of B7H4
with a subset of CD68+ myeloid cells (right). Enlarged image of the indicated region in (left) with box. Enlarged image of indicated region from the right.
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expression across the myeloid cluster, and was not restricted to
any one particular subcluster. To further confirm the cellular
localization of B7-H4, we performed imaging mass cytometry,
that demonstrated localization of B7-H4 to a subset of CD68+
myeloid cells (figure 1f).
Temporal expression of PD-L1 and B7-H4 and their
respective ligands in BBN-induced bladder cancer
Mice given BBN develop carcinoma in situ (CIS) by 2–3 months,
invasive tumors by 3 months, with progression to bulky tumors
by 4 months.41 We validated the RNA expression data presented
in Figure 1 by determining how the number of CD4+ T cells,
CD8+ T cells, and monocytes/macrophages changed over time
during BBN-induced bladder cancer development. To do so,
bladders were collected at 0.5, 1, 2, 4, and 5 months after the
initiation of BBN (Figure 2). The results show a biphasic pattern
with regard to the number of CD4+ T cells, CD8+ T cells, and
monocytes present within the bladder during BBN exposure
(Figure 2a–c). Similar to our RNA-Seq results, we identified
a peak in the numbers of pro-inflammatory T cells (CD4+ and
CD8+ T cells) at 1 month, but there is a decline in cell numbers
by 2- and 3-months concomitant with the development of car-
cinoma. During BBN exposure, the gradual increase in CD4+
Figure 2. Bi-phasic pattern of immune bladder immune infiltration during BBN-induced cancer. Male C57BL/6 mice (n = 10 mice per group for each time point) were
supplied either sterile water or sterile water containing 0.05% BBN ad libitum. On the indicated time points, 10 representative naïve control and BBN treated mice
were taken for analysis. The bladders were harvested and two random bladders within each treatment group were pooled to generate a total of five analytical
samples for flow cytometric analysis. The cells samples were gated as follows; for T cells (singlets, cells, live/CD45hi, CD3+/CD4+ or CD3+/CD8+ into flow plots for
specified T cells markers), and for monocytes (singlets, cells, live/CD45hi, CD11b+, Ly6 C+/Ly6 G− into flow plots for specified monocyte markers). The data are
presented as the mean number of each specified cell population per sample ± S.E.M. Two-way ANOVA with a Bonferroni posttest was used to determine statistical
differences between naïve control and BBN-treated mice. Asterisks indicate a statistically significant difference in the number of cells present within the bladder of
mice receiving BBN as compared to Control naïve mice analyzed at each time point – *p < .05, **p < .01, ***p < .001, ****p < .0001, respectively.
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and CD8+ T cells was associated with increased expression of the
exhaustion marker, such as PD-1 (Figure 2d–e). The numbers of
CD4+ T cells expressing the neuropilin-1/semaphorin3a (Nrp-1/
Sema3a; B7-H4 receptor)40 was increased at 1 and 5 months
(Figure 2g), while B7-H4 receptor-positive CD8+ T cells
increased at 0.5 and 1 months (Figure 2h). Monocytes
(CD11b+/Ly6 C+/Ly6 G−) increased sharply at 1 month and
subsequently decreased concordant with the decrease in T cell
numbers. The infiltrating monocytes expressed PD-L1 at
1 month with a second wave of increased expression at 5 months
(figure 2f). There was a small peak of B7-H4+ monocytes at 1
month, followed by a decline, and a second peak concordant
with tumor development and immune cell infiltration of bladder
tumors at 5 months (Figure 2i). Additionally, the bi-phasic
pattern of PD-L1 and B7-H4 expression correlated with both
the numbers of CD4+ Treg (Figure 2j) and effector CD4+ T and
CD8+ T cells (Figure 2k,l), as well as the expression of the
respective ligands, i.e., PD-1 and B7-H4 receptor. It should be
noted that we did not identify the expression of B7-H4 on
nonimmune (CD45-) cells in the BBN-induced bladder cancer
model (Supplemental Figure 2). These findings confirm B7-H4
expression by bladder-infiltrating monocytes concordant with
CD4+ and CD8+ T cells suggestive of induction of an anti-
inflammatory regulatory mechanism by monocyte-T cell inter-
action within the bladder. Based on these results, we investigated
the blockade of B7-H4 as a potential therapy to increase T cell
responses by inhibition of B7-H4-mediated T cell regulation.
Anti-B7-H4 blocks the immunoregulatory function of
B7-H4Ig and increases both mouse and human CD4+ and
CD8+ T cell function
To functionally demonstrate that anti-B7-H4 can inhibit the
regulatory function of B7-H4, we tested the ability of anti-B7-
H4 to block the immunoregulatory function of human B7-H4Ig
(hB7-H4Ig). SJL/J lymph node cells (5x105 cells/well) were
labeled with CFSE, and stimulated with anti-CD3 (1 μg/ml)
plus control Ig, hB7-H4Ig, and/or anti-B7-H4 (10 μg/ml)
(Figure 3a). While anti-B7-H4 alone did not alter the extent of
CD4+ T cell proliferation, the addition of anti-B7-H4 inhibited
hB7-H4Ig-induced suppression of CD4+ T cell proliferation. As
a secondary confirmation of the CFSE findings, replicate wells
were pulsed with 3H-TdR on Day 1 and cultures harvested on
Day 3. The level of 3H-TdR incorporation (counts per minute,
CPM) confirmed that anti-B7-H4 blocked the inhibitory func-
tion of human B7-H4Ig (Figure 3a). As a further confirmation of
Figure 3. Anti-B7-H4 blocks the immunosuppressive function of B7-H4Ig. Total LN cells were collected from naïve SJL/J mice, and cells were labeled with CFSE. CFSE-
labeled lymph node cells (5x105 cells/well) were cultured in the presence of anti-CD3 (1 µg/ml), plus Control Ig, hB7-H4Ig, anti-B7-H4, or hB7-H4Ig plus anti-B7-H4
(5 µg/ml). Replicate wells were pulsed with 1μCi of tritiated thymidine (3H-TdR) at 24 h, and the cultures were harvested on day +5. For the assessment of T cells
proliferation, the percentage of live CD4 + T cells that diluted CFSE were gated. The level of cellular proliferation is also presented on each flow histogram as
determined by 3H-TdR incorporation (Δ CPM = CPM with anti-CD3 – CPM with PBS) (a). SJL/J mice (n = 10/group) were primed with PLP139-151/CFA and treated with
species and isotype-matched Control Ig, hB7-H4Ig, anti-B7-H4, or hB7-H4Ig plus anti-B7-H4 (100 μg/dose; 3x/wk; 2wks), and mice were followed for disease severity.
The data are presented as the mean clinical score ± S.E.M. (b). On day +9 of the disease course the PLP139-151 in vivo DTH responses were assessed. The data are
presented as the mean ear swelling ± S.E.M. for both control antigen challenge (OVA323-339) and specific antigen challenge (PLP139-151) (c). One representative
experiment of three is presented. Two-way ANOVA with a Bonferroni posttest was used to determine statistical differences between the indicated treatment groups.
Asterisks (***) indicates a statistically significant decrease in the PLP139-151-induced clinical EAE or DTH response in mice B7-H4Ig treated mice in comparison to mice
treated with Control Ig, p < .001, respectively.
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the ability of anti-B7-H4 to block hB7-H4Ig function, SJL/J mice
were primed with PLP139-151/CFA, and treated 3 times per week
for 2 weeks beginning at the time of priming (Day 0) with
control Ig, hB7-H4Ig, or anti-B7-H4 as indicated. Mice were
observed for paralytic disease symptoms, as we previously
reported,5 hB7-H4Ig treatment significantly decreased disease
severity (Figure 3b). While anti-B7-H4 treatment alone did not
modulate the level of disease severity, treatment with anti-B7-H4
blocked the hB7-H4Ig-induced decrease in disease severity
(Figure 3b). In addition, anti-B7-H4 blocked the hB7-H4Ig-
induced decrease in in vivo CD4+ T cell function as measured
by delayed-type hypersensitivity (DTH) responses to ear chal-
lenge with PLP139-151. Taken together, these findings demon-
strate that anti-B7-H4 blocks hB7-H4Ig-induced regulatory
function on mouse T cell responses both in vitro and in vivo.
To determine if anti-B7-H4 could block B7-H4-induced
regulation of human T cells, CD14+ monocytes from healthy
donors were cultured for 3 days with IL-10, IL-6, and IL-10
plus IL-6 (10 ng/ml). On day 3 of culture, adherent cells
were collected and analyzed by flow cytometry for the
expression of B7-H4, CD80, CD86, PD-L1, and PD-L2.
Combined treatment of monocytes with IL-10 and IL-6
induced maximal B7-H4 expression (Figure 4a). Therefore,
we cultured monocytes with IL-10 and IL-6 for 3 days prior
to co-culture with CD4 + T cell or CD8 + T cells in the
presence of anti-CD3, control, or anti-B7-H4 antibody.
While the addition of anti-B7-H4 did not significantly
enhance proliferation of CD4+ (Figure 4b) or CD8+ T cells
(Figure 4d), anti-B7-H4 induced a significant increase in the
production of IFN-γ by both CD4+ and CD8+ T cells
(Figure 4c,e). Thus, anti-B7-H4 blockade increased the func-
tion of both human CD4+ and CD8+ T cells stimulated with
B7-H4 expressing monocytes.
Anti-B7-H4 treatment increases CD8+ T cell infiltration
into the bladder during BBN-induced bladder cancer and
IFN-γ production by splenic CD8+ T cells
After confirmation of the functional activity of our B7-H4 anti-
body, we investigated if anti-B7-H4 could modulate tumor
development in the BBN bladder cancer model. Mice were
given BBN for 4 months followed by normal drinking water
during treatment with a species and isotype-matched control
antibody, anti-PD-1, or anti-B7-H4 once weekly for four total
treatments (Figure 5a). Treatment with the anti-B7-H4 antibody
led to a decrease in the number of advanced tumors (50% stage 3
or greater compared to 70% in controls), and a significant
increase in the number of CD8+ bladder-infiltrating T cells
(Figure 5b,c). In contrast, anti-B7-H4 treatment decreased the
number of Foxp3+ Tregs (Figure 5b,d), indicating that anti-B7-
H4 treatment shifted the CD8+ T cell to Treg ratio in favor of an
anti-tumor response (Supplemental Figure 3). While treatment
Figure 4. Anti-B7-H4 treatment increase IFN-γ secretion by T cell cultured in the presence of B7-H4+ monocytes. CD14+ monocytes were sort purified from healthy
donor PBMCs (n = 5) and cells were cultured in the presence of medium alone, IL-10, IL-6, or IL-10 plus IL-6 (10 ng/ml) for 3 days. The percent of resultant monocytes
expressing B7-H4, CD80, CD86, PD-L1, and PD-L2 was assessed (a). Sort purified autologous CFSE-labeled CD4+ T cells (b, c) and CD8+ T cells (d, e) were co-cultured
with IL-10 plus IL-6 conditioned monocytes and anti-CD3 for 3 days, and the level of proliferation was assessed via flow cytometry (b, d) and the level of secreted
IFN-γ measured (c, e). Proliferation data is presented as the mean percent divided cells and concentration of IFN-γ (pg/ml) present with the culture ± S.E.M. Two-way
ANOVA with a Bonferroni posttest was used to determine statistical differences between naïve control Ab and anti-B7-H4 treated cultures. Asterisks (**) indicates
a statistically significant difference as compared to the control Ab treated cultures, p < .01, respectively.
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of mice with anti-PD-1 or anti-B7-H4 did not alter the number
of total splenic CD45hi cells, CD4+ T cells, or CD8+ T cells
present within the spleen (Figure 5e), both anti-PD-1 and anti-
B7-H4 treatments significantly increased the number of CD8+/
IFN-γ+ cells present within the spleen compared to control Ab-
treated mice (figure 5f). Total splenocytes from the treatment
groups were activated ex vivo in the presence of anti-CD3 for
3 days to assess levels of cytokine secretion. Splenocytes from
anti-B7-H4-treated mice secreted significantly higher levels of
IFN-γ in response to anti-CD3 stimulation, as compared to
T cells from control Ab or anti-PD-1 treated mice (Figure 5g).
We also evaluated the gene expression profile of anti-B7-H4
treated mice, and found reestablishment of normal gene expres-
sion associated with urothelium differentiation. These changes
included increased expression of bladder muscle/detrusor-
related pathway transcripts, the urothelial differentiation
Figure 5. Anti-B7-H4 treatment increases CD8+ T cell function. (a) Treatment schema of mice for comparison of anti-tumor response of IgG, anti-PD1 and anti-B7-H4
antibodies. (b) Representative immunohistochemistry sections of BBN tumors for anti-CD8 (top) and anti-Foxp3 (bottom) staining. All images are at low-power
(100X). Quantification of the average number of CD8+(c) and Foxp3+ (d) immune cells per low-power field. The number (e) and percentage (f) of singlet/live/CD45hi
cell that were CD4+/IFN-γ+, CD8+/IFN-γ+, or CD4+/CD25+/Foxp3+ present within the spleens was assessed by flow cytometry. The data are presented as the mean cell
number or percentage of cells ± S.E.M. Total splenocytes were cultured in the presence of anti-CD3 (1 μg/ml) for 3 days and the level of secreted cytokine assessed.
The data are presented as the mean pg/ml of secreted cytokine (g). Two-way ANOVA with a Bonferroni posttest was used to determine statistical differences
between the indicated treatment groups. Asterisks (*, **, ****) indicates a statistically significant difference as compared to the control Ab-treated mice, p < .05, 0.01,
0.001, respectively. (h) BBN mice treated with anti-PD-1 and anti-B7-H4 had lower rates of T2 or higher (detrusor muscle invasion and greater) cancer compared to
anti-PD1 or anti-B7-H4 alone. (i) Tumor area/bladder section (expressed a percentage of bladder section) was compared from mice with different treatments (j)
Tumor necrosis (expressed as a percentage of necrosis/tumor area) was also compared between treatment types. (k) Mechanistic cartoon of proposed function B7-H4
and blockade of B7-H4 by antibody in bladder cancer.
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transcript (uroplakin 3b), and decreased the expression of cell-
cycle progression, mitosis, and cell-cycle checkpoint transcripts
(Supplemental Figure 5). Most prominently, the response to B7-
H4 was associated with decreased expression of the oncogenes
Hoxb9, H19, and Egln3. The data also show metabolic changes
suggestive of increased aerobic pathway usage, including the
expression of Car2 (carbonic anhydrase), adh1 (alcohol dehy-
drogenase), and Pck1. These findings indicate that anti-B7-H4
treatment of BBN mice induced an increase in CD8+ T cell
infiltration into the bladder and increased the level of IFN-γ
secreted per splenic CD8+ T cell, while decreasing the number of
Tregs present within the bladder.
Lastly, we showed that anti-B7-H4 therapy synergized with
anti-PD-1 therapy, which is the current standard of care for
metastatic and chemotherapy-resistant bladder cancer. The
co-treatment of mice with anti-B7-H4 and anti-PD-1 resulted
in a significant reduction in advanced stage tumors (80% in
vehicle-treated mice vs. 60% in anti-B7-H4 treated mice; and
40% in combination treated mice (Figure 5h) (p = .017),
decreased tumor area (51% tumor in vehicle vs. 19%,
p < .009), and a trend toward increased tumor necrosis (6%
in vehicle vs. 28%, p < .07) (Figure 5j). This suggests that the
targeting of two different regulatory pathways may produce
a great patient response to ICB therapy.
Discussion
Bladder cancer, similar to other solid tumors attributed to carci-
nogen exposure including lung cancer and melanoma, is asso-
ciated with a high total mutation burden at approximately seven
mutations/MB.42 Systemic immunotherapy has changed the
survival of patients with bladder cancer for those unresponsive
to cisplatin (CIS) chemotherapy, or unable to received
chemotherapy with a median progression-free survival of
10.3 months (95% confidence interval [CI], 8.0 to 11.8) com-
pared with 7.4 months (95% CI, 6.1 to 8.3) in those treated with
chemotherapy (hazard ratio for death, 0.73; 95% CI, 0.59 to 0.91;
P = .002).24 Recent application of anti-PD-1 and anti-PD-L1
therapy in the neoadjuvant setting has shown promising results
with decreased pathologic stage and potentially improved recur-
rence-free survival.43 Yet, less than 20% of patients treated with
checkpoint immunotherapy have a clinical response and even in
those with MIBC, choosing the right systemic therapy prior to
cystectomy remains critical for limiting toxicity prior to surgery.
Until the early reports of Phase III trials of Atezolizumab and
Pembrolizumab in the first-line metastatic setting, the value to
PD-L1 testing was unclear. Yet, inferior reports of response to
PD-L1 low or non-expressing tumors in May of 2018 resulted in
label changes for both Atezolizumab and Pembrolizumab con-
firming the critical association of PD-L1 immunohistochemical
marker activity with the response to each therapy. Thus, patients
that are PD-L1 “negative” have a low likelihood of response and
are unlikely to benefit from systemic therapy targeting PD-1/
PD-L1.44 Due to the limitations of the current landscape of PD-
1/PD-L1 therapy for bladder cancer patients, investigation of
other immune checkpoints is a necessity for those unlikely to
respond to PD-1/PD-L1. In our evaluation of MIBC, we found
that B7-H4 is expressed in higher levels in luminal and luminal
papillary tumors. This distinction separates B7-H4 from CTLA-
4 and PD-L1 which are expressed at higher levels in basal-type
cancers. While tumor subtyping has been performed in a small
series of patients treated with anti-PD-1/PD-L1, luminal and
luminal papillary tumors are the poorest responders (unpub-
lished data and23,45)
To identify potential immune regulatory mechanisms
involved in the immune-editing of bladder cancer, we profiled
the immune landscape of the mouse BBN bladder cancer
model from 2 to 20 weeks post-initiation of C57BL/6 mice
receiving BBN containing water. Our group has previously
validated the genomic alterations that develop in this model.38
To our knowledge, we are the first to describe the immune
activation that is bi-modal after BBN treatment. The present
data show that there is an acute inflammatory phase that
starts within 2 weeks, but then decreases between four and
12 weeks. While we observed invasion of the bladder by
lymphocytes between two and 4 weeks after BBN exposure,
expression of regulatory monocyte and T cell populations
potentially decrease the effector CD4+ and CD8+ T cells pre-
sent within the bladder until the tumor develops at 3 months.
With the development of CIS and invasive bladder cancer, the
number of tumors infiltrating lymphocytes increases, but
these cells express markers of exhaustion (PD-L1) indicating
that these cells are likely not effective in controlling tumor cell
growth. Upregulation of B7-H4 expression was observed in
monocytes in the BBN-treated mice, preceding both the
decrease in CD8+ T cells and an increase in Tregs. This led
to further functional studies of B7-H4 in the BBN bladder
cancer model.
Across the various types of solid human tumors, the expres-
sion of B7-H4 is associated with worse patient survival.18-20
High expression of B7-H4 has been described in ovarian,
endometrial, gastric, renal cell, melanoma, breast, lung, color-
ectal, pancreatic, and prostate cancer. Mechanistic investigation
of B7-H4 in liver cancer identified that targeting B7-H4 geneti-
cally resulted in increased proliferation of CD8+ T cells with
decreased levels of exhaustion transcription factors.21 In the
current study, we confirmed that anti-B7-H4 treatment
increased CD8+ T cell activation as a mechanism of immune
activation. Additionally, we found lower numbers of Foxp3+
Tregs present within the bladders of mice receiving anti-B7-H4
treatment, thereby indicating that a regulatory phenotype of the
TILs had shifted toward an anti-tumor phenotype.
In addition to effects on Tregs, receptor ligation by the
immune modulatory molecules, such as B7-H4, have been sug-
gested to directly alter the phenotype of CD4+ T cells.46,47 Co-
culture of CD4+ T cells with IL-10/TGF-β treated macrophages
expressing B7-H4 decreased CD4+ T cell proliferation and
increased the number of Foxp3+ CD4+ T cells.48 Published
data show that hB7-H4Ig binds to CD4+ T cells in an activation-
dependent manner, indicating that B7-H4 may function as a co-
inhibitory (negative co-stimulatory) molecule for CD4+
T cells.5,46,49 The present data show that B7-H4 also directly
interacts with a functional B7-H4 receptor on CD8 + T cells, as
the addition of anti-B7-H4 to monocyte/CD8+ T cell co-cultures
induced a significant increase in the level of secreted IFN-γ
(Figure 4e). This is supported by our previous findings showing
that hB7-H4Ig can down-regulate IL-17 and IFN-γ production
of mouse T cells in the absence of Tregs.5 Further, our in vivo
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data show that treatment of C57BL/6 mice with BBN-induced
bladder cancer significantly increased the number of CD8+
T cells and a significantly decreased the number of Tregs present
within the bladder (Figure 5c,d). This finding correlated with an
increase in the percentage of IFN-γ+/CD8+ T cells present within
the spleen and a significant decrease in tumor stage as compare
to control Ab-treated mice. The only other investigation of
immunotherapy in the BBN model reported that the ratio of
CD8+ T cell to Treg cells was associated with response to anti-
PD-1 antibody treatment.50 While the present data show the
functionality of anti-B7-H4 treatment in the presence of mono-
cyte expressed B7-H4, B7-H4 expression by tumor cells is also
a putative mechanism by which these cells evade anti-tumor
immune responses. In the majority of breast and ovarian can-
cers, B7-H4 mRNA is expressed at approximately two-fold or
greater than the level expressed within normal tissue,51 and B7-
H4 protein is present in half of early-stage and two-thirds of late-
stage ovarian tumors.52 Additionally, tumor tissues from breast,
uterus, ovary, colon, and pancreas showed a statistically signifi-
cant increase in the percentage of cells expressing B7-H4.53 In
the 4T1 metastatic breast cancer model, the transfer of tumor
cells into B7-H4−/- versus wildtype mice resulted in fewer lung
nodules, enhanced survival, and decreased tumor infiltration of
immunosuppressive cells.54 Based on these findings, expression
of B7-H4 within the tumor microenvironment, either by the
tumor cells and/or by infiltrating monocytes, is hypothesized
to promote immune evasion. In support of this hypothesis,
published data show that stimulation of the B7-H4 receptor
complex via hB7-H4Ig treatment in the PLP139-151/CFA model
of relapsing-remitting EAE increased the number and function
of Tregs.5
Our investigation identified B7-H4 as a negative regulator of
T cell activity in the bladder during cancer development. The
present data show that the treatment of C57BL/6 male mice
receiving BBN containing water with anti-B7-H4 increases the
number of CD8+ T cells and decreases the number of Tregs
present within the bladder (Figure 5k). The anti-B7-H4 treat-
ment-induced skewing of the CD8+ T cell to Treg ratio within
the bladder correlated with a decrease in the bladder cancer stage
score. Additionally, co-treatment of mice with both anti-B7-H4
and anti-PD-1 further decreased bladder cancer stage score, and
such combination therapy may be considered a target for future
therapeutic trials in patients with bladder cancer.
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